4.7 Article

Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter

Related references

Note: Only part of the references are listed.
Review Oncology

Tailoring the approach to radioactive iodine treatment in thyroid cancer

Sarah E. Mayson et al.

Summary: The treatment of differentiated thyroid cancer is moving towards individualized therapeutic decision-making, with a focus on risk stratification to determine the use of radioactive iodine (RAI). RAI can be safely deferred for low-risk patients, while adjuvant RAI may benefit higher-risk patients.

ENDOCRINE-RELATED CANCER (2021)

Article Radiology, Nuclear Medicine & Medical Imaging

Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer

Tadashi Watabe et al.

Summary: High doses of [At-211]NaAt administration resulted in weight loss, transient bone marrow suppression, and pathological changes in the testis, which need to be considered in the first-in-human clinical trial.

ANNALS OF NUCLEAR MEDICINE (2021)

Review Radiology, Nuclear Medicine & Medical Imaging

Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update

Anthony Ciarallo et al.

AMERICAN JOURNAL OF ROENTGENOLOGY (2020)

Article Radiology, Nuclear Medicine & Medical Imaging

Enhancement of 211At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer

Tadashi Watabe et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

Review Endocrinology & Metabolism

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy

Jierui Liu et al.

ENDOCRINOLOGY AND METABOLISM (2019)

Editorial Material Endocrinology & Metabolism

Definition and management of radioactive iodine-refractory differentiated thyroid cancer

Martin Schlumberger et al.

LANCET DIABETES & ENDOCRINOLOGY (2014)